Stefania P. Bjarnarson

Stefania P. Bjarnarson

Auto-generated profile, based on publicly available information

Stefania P. Bjarnarson

Faculty of Medicine, Biomedical Center, School of Health Sciences, University of Iceland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2011 in Nature Communications
Verified
Journal Article
Open access
NSNigel M. Stapleton
Nigel M. Stapleton
JAJan Terje Andersen
Jan Terje Andersen
ASAnnette M. Stemerding
Annette M. Stemerding
SBStefania P. Bjarnarson
Stefania P. Bjarnarson
RVRuurd C. Verheul
Ruurd C. Verheul
Gestur VidarssonGestur Vidarsson
Gestur Vidarsson
Human IgG3 displays the strongest effector functions of all IgG subclasses but has a short half-life for unresolved reasons. Here we show that IgG3 binds to IgG-salvage receptor (FcRn), but that FcRn-mediated transport and rescue of IgG3 is inhibited in the presence of IgG1 due to intracellular competition between IgG1 and IgG3. We reveal that this occurs because of a single amino acid difference at position 435, where IgG3 has an arginine instead of the histidine found in all other IgG subclasses. While the presence of R435 in IgG increases binding to FcRn at neutral pH, it decreases binding at acidic pH, affecting the rescue efficiency-but only in the presence of H435-IgG. Importantly, we show that in humans the half-life of the H435-containing IgG3 allotype is comparable to IgG1. H435-IgG3 also gave enhanced protection against a pneumococcal challenge in mice, demonstrating H435-IgG3 to be a candidate for monoclonal antibody therapies.

1 October 2005 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
SKSigurdur Kristjansson
Sigurdur Kristjansson
SBStefania P. Bjarnarson
Stefania P. Bjarnarson
GWGöran Wennergren
Göran Wennergren
APAslaug H. Palsdottir
Aslaug H. Palsdottir
TAThorgerdur Arnadottir
Thorgerdur Arnadottir
IJIngileif Jonsdottir
Ingileif Jonsdottir

1 March 2002 in Infection and Immunity
Verified
Journal Article
Closed access
PDF file
HJHåvArd Jakobsen
HåvArd Jakobsen
SBStefania Bjarnarson
Stefania Bjarnarson
GGGiuseppe Del Giudice
Giuseppe Del Giudice
MMMonique Moreau
Monique Moreau
CSClaire-Anne Siegrist
Claire-Anne Siegrist
IJIngileif Jonsdottir
Ingileif Jonsdottir
Immunization with pneumococcal polysaccharides (PPS) conjugated to tetanus toxoid (TT) (Pnc-TT) elicits protective immunity in an adult murine pneumococcal infection model. To assess immunogenicity and protective immunity in early life, neonatal (1 week old) and infant (3 weeks old) mice were immunized intranasally (i.n.) or subcutaneously (s.c.) with Pnc-TT of serotype 1 (Pnc1-TT). Anti-PPS-1 and anti-TT immunoglobulin G (IgG) and IgM antibodies were measured in serum and saliva, and vaccine-induced protection was evaluated by i.n. challenge with serotype 1 pneumococci. Pnc1-TT was immunogenic in neonatal and infant mice when administered s.c. without adjuvant: a majority of the young mice were protected from bacteremia and a reduction of pneumococcal density in the lungs was observed, although antibody responses and protective efficacy remained lower than in adults. The addition of LT-K63, a nontoxic mutant of heat-labile enterotoxin, as adjuvant significantly enhanced PPS-1-specific IgG responses and protective efficacy following either s.c. or i.n. Pnc1-TT immunization. Mucosal immunization was particularly efficient in neonates, as a single i.n. dose of Pnc1-TT and LT-K63 induced significantly higher PPS-1-specific IgG responses than s.c. immunization and was sufficient to protect neonatal mice against pneumococcal infections, whereas two s.c. doses were required to induce complete protection. In addition, i.n. immunization with Pnc1-TT and LT-K63 induced a vigorous salivary IgA response. This suggests that mucosal immunization with pneumococcal conjugate vaccines and LT-K63 may be able to circumvent some of the limitations of neonatal antibody responses, which are required for protective immunity in early life.

8 September 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
FMFrancesca Micoli
Francesca Micoli
SBStefania P. Bjarnarson
Stefania P. Bjarnarson
MAMelissa Arcuri
Melissa Arcuri
APAudur Anna Aradottir Pind
Audur Anna Aradottir Pind
GMGudbjorg J. Magnusdottir
Gudbjorg J. Magnusdottir
ASAllan Saul
Allan Saul
Polysaccharide-protein conjugates have been developed to overcome the T-independent response, hyporesponsiveness to repeated vaccination, and poor immunogenicity in infants of polysaccharides. To address the impact of polysaccharide length, typhoid conjugates made with short- and long-chain fractions of Vi polysaccharide with average sizes of 9.5, 22.8, 42.7, 82.0, and 165 kDa were compared. Long-chain-conjugated Vi (165 kDa) induced a response in both wild-type and T cell-deficient mice, suggesting that it maintains a T-independent response. In marked contrast, short-chain Vi (9.5 to 42.7 kDa) conjugates induced a response in wild-type mice but not in T cell-deficient mice, suggesting that the response is dependent on T cell help. Mechanistically, this was explained in neonatal mice, in which long-chain, but not short-chain, Vi conjugate induced late apoptosis of Vi-specific B cells in spleen and early depletion of Vi-specific B cells in bone marrow, resulting in hyporesponsiveness and lack of long-term persistence of Vi-specific IgG in serum and IgG+ antibody-secreting cells in bone marrow. We conclude that while conjugation of long-chain Vi generates T-dependent antigens, the conjugates also retain T-independent properties, leading to detrimental effects on immune responses. The data reported here may explain some inconsistencies observed in clinical trials and help guide the design of effective conjugate vaccines. Significance Our results suggest a rational way of designing and developing an improved typhoid conjugate vaccine and, by extension, to conjugate vaccines in general: first, modify a T-independent polysaccharide so that it no longer induces a T-independent response, then conjugate the polysaccharide to a suitable carrier protein restoring immunogenicity, thus creating a pure T-dependent antigen that induces a strongly boostable and long-lived response at an early age.

7 December 2011 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
SBSiggeir Fannar Brynjolfsson
Siggeir Fannar Brynjolfsson
MHMaren Henneken
Maren Henneken
SBStefania P. Bjarnarson
Stefania P. Bjarnarson
EMElena Mori
Elena Mori
GGGiuseppe Del Giudice
Giuseppe Del Giudice
IJIngileif Jonsdottir
Ingileif Jonsdottir
Background. Repeated immunizations with polysaccharide (PS) vaccines cause hyporesponsiveness through undefined mechanisms. We assessed the effects of a PS booster on immune responses, frequency, and survival of PS-specific B-cell subpopulations in spleen and bone marrow. Methods. Neonatal mice were primed with meningococcus serotype C (MenC) conjugate MenC-CRM197+CpG1826, boosted with MenC-CRM197, MenC-PS, or saline; subsequently, bromodeoxyuridine (BrdU) was injected daily intraperitoneally. MenC-PS–specific cells were labeled with fluorescent MenC-PS and phenotyped by flow cytometry. Results. After MenC-PS booster, proliferating (BrdU+) MenC-PS–specific naive B cells (CD138−/B220+; P = .0003) and plasma cells (CD138+/B220−; P = .0002) in spleen were fewer than after saline booster. BrdU+ MenC-PS–specific plasma cells were also reduced in bone marrow (P = .0308). Compared to saline, MenC-PS booster reduced BrdU+ IgG+ MenC-PS–specific B cells in spleen (P = .0002). Twelve hours after the MenC-PS booster, an increased frequency of apoptotic (AnnexinV+) MenC-PS–specific B cells in spleen was observed compared with MenC-CRM197 (P = .0286) or saline (P = .001) boosters. Conclusions. We demonstrated that the MenC-PS booster significantly reduced the frequency of newly activated MenC-PS–specific B cells—mostly switched IgG+ memory cells—by driving them into apoptosis. It shows directly that apoptosis of PS-specific memory cells is the cause of PS-induced hyporesponsiveness. These results should be taken into account prior to consideration of the use of PS vaccines.

9 March 2005 in European Journal of Immunology
Verified
Journal Article
Open access
PDF file
SBStefania P. Bjarnarson
Stefania P. Bjarnarson
HJHåvard Jakobsen
Håvard Jakobsen
GGGiuseppe Del Giudice
Giuseppe Del Giudice
ETEmanuelle Trannoy
Emanuelle Trannoy
CSClaire‐Anne Siegrist
Claire‐Anne Siegrist
IJIngileif Jonsdottir
Ingileif Jonsdottir
The aim of vaccination is to rapidly elicit protective immunity and generate memory for sustained protection. We studied the induction and persistence of polysaccharide (PS)‐specific memory in neonatal and infant mice primed with pneumococcal conjugate (Pnc1‐TT) by assessing the response to native pneumococcal PS (PPS‐1), the kinetics of the PPS‐1‐specific IgG response to a second Pnc1‐TT dose and affinity maturation. A subcutaneous (s.c.) Pnc1‐TT booster induced a rapid increase in PPS‐1‐specific IgG, indicating efficient priming for memory by a single dose of Pnc1‐TT already at 1 week of age. High levels were maintained for >12 weeks. However, a PPS‐1 booster induced no response in neonatal or infant mice. The adjuvant LT‐K63 significantly enhanced the IgG response and affinity to Pnc1‐TT by both the s.c. and the intranasal (i.n.) route in all age groups. In neonatal and infant mice, PPS‐1 and LT‐K63 induced a booster response only when given i.n. following either s.c. or i.n. priming with Pnc1‐TT and LT‐K63. In contrast, PPS‐1 with or without LT‐K63 administered s.c. compromised the ongoing PPS‐1‐specific response elicited in neonatal mice by either s.c. or i.n. priming with Pnc1‐TT and LT‐K63. These results demonstrate the advantage of the mucosal route for elicitation of PS‐specific memory responses in early life.